Huntington's Disease News and Research

Latest Huntington's Disease News and Research

Lonza, Benitec partner to develop scalable manufacturing process for AAV-based viral gene therapies

Lonza Houston, Inc., a global leader in biological, cell and viral gene therapy manufacturing, and Benitec Biopharma, a clinical stage biotechnology company commercializing a patented gene-silencing technology, DNA-directed RNA interference (ddRNAi), today announced that they have entered into a Manufacturing Services Agreement to develop a scalable manufacturing process for Benitec's ddRNAi-based, Adeno-Associated Virus (AAV)-delivered products intended for therapeutic use in humans.

7 Oct 2015

Songbirds may help researchers find cure for Huntington’s disease

Many neurological disorders can rob someone of the ability to speak clearly, causing them to stutter, mispronounce words, and struggle to put together coherent sentences. However, the molecular and neurological dysfunctions that cause these symptoms aren't well understood. Recent work at The Rockefeller University may give researchers a new tool to better study these vocal and speech impairments, particularly in Huntington's disease.

6 Oct 2015

Novel approach promises easier way to detect protein fibers implicated in neuro-degenerative diseases

Liquid crystals are familiar to most of us as the somewhat humdrum stuff used to make computer displays and TVs. Even for scientists, it has not been easy to find other ways of using them.

24 Sep 2015

Researchers develop new method to capture how brain cells interact

Interactions between brain cells hold the key to healthy brain function and cognition, but many of those interactions are notoriously difficult to study.

21 Sep 2015

Benitec Biopharma initiates new site for ongoing Phase 1/2a TT-034 trial for hepatitis C

Benitec Biopharma Limited, a clinical-stage biotechnology company developing innovative therapeutics based on its gene-silencing technology, DNA-directed RNA interference (ddRNAi), is pleased to announce it has initiated a new site for its ongoing Phase 1/2a TT-034 trial at the Methodist Health System Clinical Research Institute in Dallas, Texas.

16 Sep 2015

Shire and Sangamo revise agreement to expedite development of ZFP Therapeutics for Huntington's disease, hemophilia A and B

Sangamo BioSciences, Inc., a leader in therapeutic genome editing, announced today that the company and its collaborator, Shire plc, have agreed to revise their January 2012 collaboration and license agreement to expedite the development of ZFP Therapeutics for hemophilia A and B and Huntington's disease.

2 Sep 2015

Huntington’s disease prevention breakthrough? An interview with Professor Lesley Jones

Huntington’s disease is an inherited disease which, whilst quite rare, is one of the more common inherited neurodegenerative diseases. About 1 in 6,000 people in the UK are at risk and what’s horrible about this disease is that if one of your parents has it, then you have a fifty-fifty chance of inheriting it.

2 Sep 2015

Benitec Biopharma announces closing of U.S. initial public offering of ADSs

Benitec Biopharma Limited, a clinical-stage biotechnology company, is pleased to announce the closing of its U.S. initial public offering of 1,500,000 American Depositary Shares (ADSs), representing 30,000,000 fully paid ordinary shares of Benitec, together with warrants to purchase 500,000 ADSs, representing 10,000,000 fully paid ordinary shares.

24 Aug 2015

NYBC, UC Davis Health System partner to manufacture potential stem cell therapies

New York Blood Center today announced a new collaboration with the University of California, Davis, Health System to manufacture specialized lines of stem cells as potential therapies for repair and regeneration of retina, kidney, lung and liver tissue, as well as for the treatment of neurodegenerative disorders such as Parkinson's, Alzheimer's and Huntington's disease.

20 Aug 2015

Benitec prices initial public offering of 1,500,000 American Depositary Shares

Benitec Biopharma Limited, a clinical-stage biotechnology company, is pleased to announce the pricing of its U.S. initial public offering of 1,500,000 American Depositary Shares (ADSs), representing 30,000,000 fully paid ordinary shares of Benitec and warrants to purchase 500,000 ADSs, representing 10,000,000 fully paid ordinary shares, at a price of US$9.21 per ADS and US$0.01 per warrant.

18 Aug 2015

Omeros reports additional positive data from OMS721 Phase 2 trial for treatment of thrombotic microangiopathies

Omeros Corporation today announced additional positive data in the company's Phase 2 clinical trial of OMS721 for the treatment of thrombotic microangiopathies (TMAs). TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) – aggregations of platelets – in the microcirculation of the body's organs, most commonly the kidney and brain.

18 Aug 2015

CMU BrainHub scientists use non-invasive brain-imaging tool to detect basal ganglia pathways

Certain diseases, like Parkinson's and Huntingdon's disease, are associated with damage to the pathways between the brain's basal ganglia regions. The basal ganglia sits at the base of the brain and is responsible for, among other things, coordinating movement. It is made up of four interconnected, deep brain structures that imaging techniques have previously been unable to visualize.

18 Aug 2015

Omeros plans to file patent infringement lawsuit against Par

Omeros Corporation today, in response to investor questions, announced that it plans to file a patent infringement lawsuit against Par Pharmaceutical, Inc. and its subsidiary, Par Sterile Products, LLC in response to the Abbreviated New Drug Application (ANDA) filed by Par seeking FDA approval to market a generic version of Omeros' commercial drug Omidria (phenylephrine and ketorolac injection) 1%/0.3%.

17 Aug 2015

Determining the dynein-dynactin complex structure: an interview with Dr Gabriel C. Lander

This is a macromolecular assembly is made up of two components, dynein and dynactin, that works to move molecular cargo (organelles, RNA, vesicles, proteins, viruses) along microtubule highways within our cells.

16 Aug 2015

FDA accepts sNDA to review Brintellix clinical trial data for treatment of major depressive disorder

Takeda Pharmaceutical Company Limited (Takeda) and H. Lundbeck A/S (Lundbeck) announced today the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for review to add clinical data regarding the effect of Brintellix (vortioxetine) on certain aspects of cognitive function in adults with Major Depressive Disorder (MDD) to the current product label.

11 Aug 2015

Researchers report role of two gene-regulating molecules in Parkinson's disease

As Parkinson's disease progresses in patients, a puzzling dichotomy plays out in their brains. One set of neurons degenerates, while a similar population nearby is spared the same degree of damage. Why the difference? An answer to this question could clear the way for preventions and treatments for this disease, which impairs movement.

11 Aug 2015

Discovery may lead to new ways to diagnose, treat brain cancer

Researchers at the Virginia Bioinformatics Institute have uncovered a link between the genomes of cells originating in the neural crest and development of tumors — a discovery that could lead to new ways to diagnose and treat cancer.

6 Aug 2015

Omeros receives EC approval to market Omidria in EU and other European countries

Omeros Corporation today announced that the European Commission (EC) has granted marketing authorization for Omidria (phenylephrine and ketorolac injection) 1% / 0.3% in the European Union (EU) for use in cataract surgery and lens replacement procedures to maintain mydriasis (pupil dilation), prevent miosis (pupil constriction), and to reduce postoperative eye pain.

3 Aug 2015

Redox equilibrium may help identify new diagnostic biomarkers for ageing, neurodegenerative processes

The question of why we age is one of the most fascinating questions for humankind, but nothing close to a satisfactory answer has been found to date.

3 Aug 2015

DNA study reveals potential treatments to delay or prevent onset of Huntington's disease

Scientists from Cardiff University believe that a treatment to prevent or delay the symptoms of Huntington’s disease could now be much closer, following a major breakthrough.

31 Jul 2015

Huntington's Disease News and Research

Latest Huntington's Disease News and Research

Lonza, Benitec partner to develop scalable manufacturing process for AAV-based viral gene therapies

Songbirds may help researchers find cure for Huntington’s disease

Novel approach promises easier way to detect protein fibers implicated in neuro-degenerative diseases

Researchers develop new method to capture how brain cells interact

Benitec Biopharma initiates new site for ongoing Phase 1/2a TT-034 trial for hepatitis C

Shire and Sangamo revise agreement to expedite development of ZFP Therapeutics for Huntington's disease, hemophilia A and B

Huntington’s disease prevention breakthrough? An interview with Professor Lesley Jones

Benitec Biopharma announces closing of U.S. initial public offering of ADSs

NYBC, UC Davis Health System partner to manufacture potential stem cell therapies

Benitec prices initial public offering of 1,500,000 American Depositary Shares

Omeros reports additional positive data from OMS721 Phase 2 trial for treatment of thrombotic microangiopathies

CMU BrainHub scientists use non-invasive brain-imaging tool to detect basal ganglia pathways

Omeros plans to file patent infringement lawsuit against Par

Determining the dynein-dynactin complex structure: an interview with Dr Gabriel C. Lander

FDA accepts sNDA to review Brintellix clinical trial data for treatment of major depressive disorder

Researchers report role of two gene-regulating molecules in Parkinson's disease

Discovery may lead to new ways to diagnose, treat brain cancer

Omeros receives EC approval to market Omidria in EU and other European countries

Redox equilibrium may help identify new diagnostic biomarkers for ageing, neurodegenerative processes

DNA study reveals potential treatments to delay or prevent onset of Huntington's disease

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Huntington's Disease News and Research

Latest Huntington's Disease News and Research

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Newsletters you may be interested in